Related Experiment Video
Updated: Apr 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation for cardioversion of atrial arrhythmias
J Mayet1, R S More, G C Sutton
1Department of Cardiology, Hillingdon Hospital, London, U.K.
Insights
For patients undergoing cardioversion for atrial fibrillation or flutter, 3 weeks of anticoagulation before and 4 weeks after is recommended. Transoesophageal echocardiography can help select patients who may not need prior anticoagulation.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Atrial fibrillation and flutter are common arrhythmias.
- Cardioversion is a procedure to restore normal heart rhythm.
- Anticoagulation is crucial to prevent stroke during cardioversion.
Purpose of the Study:
- To provide recommendations for anticoagulation management in patients undergoing cardioversion for atrial fibrillation or flutter.
- To evaluate the role of transoesophageal echocardiography in guiding anticoagulation strategies.
Main Methods:
- Review of current guidelines and clinical evidence.
- Analysis of anticoagulation protocols for elective and acute cardioversion.
- Consideration of transoesophageal echocardiography use.
Main Results:
- Advocates 3 weeks of anticoagulation prior to and 4 weeks post-cardioversion for chronic cases.
- Suggests immediate heparin for acute presentations, with transoesophageal echocardiography to exclude thrombi before cardioversion if no spontaneous reversion.
- Recommends 4 weeks of oral anticoagulation post-procedure.
- Proposes 3 weeks of anticoagulation followed by elective cardioversion and 4 weeks post-procedure if transoesophageal echocardiography is unavailable.
Conclusions:
- Anticoagulation duration is critical for stroke prevention in cardioversion.
- Transoesophageal echocardiography can personalize anticoagulation strategies.
- A standardized approach to anticoagulation improves patient safety during cardioversion.
Abstract:
We would advocate 3 weeks of anticoagulation prior to, and 4 weeks post-cardioversion (either electrical or chemical) for patients in chronic atrial fibrillation or flutter. In selected cases it seems reasonable to use transoesophageal echocardiography to exclude preformed thrombus and negate the need for 3 weeks of prior anticoagulation. For patients presenting acutely with atrial fibrillation or flutter we suggest anticoagulating with heparin immediately on presentation and for those who do not spontaneously revert to sinus rhythm, using transoesophageal echocardiography to exclude atrial thrombi prior to cardioversion. Oral anticoagulation should be continued for 4 weeks post-procedure. If transoesophageal echocardiography is not readily available an alternative strategy would be to anticoagulate the patient for 3 weeks and thereafter readmit them for elective cardioversion, continuing the anticoagulation for a further 4 weeks after the procedure.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Venous Thrombosis III: Interprofessional Care
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

